Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

Eli Lilly is investing $6.5 billion in a new active pharmaceutical ingredient (API) manufacturing facility in Houston, Texas, as part of a larger $27 billion U.S. manufacturing expansion13.

The new site will specifically support production of orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist for obesity, with expectations to submit for global regulatory approval by the end of the year3.

The project is set to create 615 permanent high-wage jobs and 4,000 construction jobs, contributing significantly to the local economy13.

Advanced technologies such as AI, machine learning, and digital automation will be used in the facility to reduce dependency on foreign supply chains and drive efficiency in pharmaceutical production13.

The facility is expected to become operational within five years and is positioned to help Lilly capture a share of the projected $100 billion obesity market by 20301.

Lilly's investment is part of a strategic move to reshore U.S. pharmaceutical manufacturing, taking advantage of Texas' business incentives and skilled workforce13.

The site was selected from more than 300 applicants based on business environment, workforce potential, local incentives, utilities, and transportation access3.

Sources:

1. https://www.ainvest.com/news/eli-lilly-6-5-billion-texas-facility-strategic-bet-pharma-sufficiency-2509/

3. https://www.plantservices.com/industry-news/news/55318855/eli-lilly-and-company-invests-65-billion-to-build-pharmaceutical-manufacturing-facility-in-texas